Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
281-300 of 1,782 trials

Hip Replacement Pain Management: Néfopam Study

We are studying the effects of néfopam on pain relief after hip replacement surgery. This trial compares its use against a placebo to see if it helps reduce the need for morphine and improves recovery.

Hip Replacement Surgery6-12 monthsConfirmation phase (III)Standard MedicinesInternal MedicineOrthopedics and Traumatology

Alectinib for Pediatric ALK Fusion-Positive Tumors

We are studying the safety and effectiveness of alectinib in children with solid or CNS tumors that have not responded to other treatments. This trial aims to find the best dose and understand how the drug works in young patients.

Malignant Mast Cell TumorsALK Fusion-Positive Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Primary Biliary Cholangitis: Bezafibrate Treatments

We are studying the effects of two doses of bezafibrate in patients with primary biliary cholangitis who aren't responding well to current therapy. The goal is to see if these treatments can improve symptoms and liver health.

Primary Biliary Cholangitis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesGastroenterologyHepatology

Nicotinamide for Liver Fibrosis in Type 2 Diabetes

We are studying whether nicotinamide can help slow liver fibrosis in people with type 2 diabetes. The trial will also assess safety and other health factors related to obesity.

Hepatic Fibrosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDiabetologyEndocrinologyHepatology

Hunter Syndrome: Long-Term Safety of Idursulfase-IT and Elaprase®

We are studying the long-term safety of a treatment combining intrathecal idursulfase-IT and intravenous Elaprase® for individuals with Hunter syndrome and cognitive impairment. This research aims to ensure the safety of these therapies over time.

Hunter's SyndromeConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyInternal MedicineNeurology

Breast Cancer: Stopping CDK4/6 Inhibitors

We are studying whether stopping CDK4/6 inhibitors helps maintain disease stability in patients with metastatic HR positive, HER2 negative breast cancer. This trial involves patients who have had stable disease after long-term treatment.

Metastatic HR Positive, HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Chronic Pancreatitis: Metamizole for Pain Relief

We are investigating whether adding metamizole to existing pain treatments helps reduce pain in patients with chronic pancreatitis diagnosed within the last three years.

Chronic Pancreatitis1-2 yearsMonitoring phase (IV)Standard MedicinesGastroenterologyInternal Medicine

HER2-Negative Breast Cancer: Pembrolizumab and Radiation Therapy

We are studying a new treatment combining immunotherapy and radiation for patients with HER2-negative breast cancer who haven't responded to initial chemotherapy. The goal is to see if this approach improves cancer response and quality of life.

HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)Standard MedicinesOncology

Advanced Ovarian Cancer: Comparing Treatment Combinations

We are studying two different drug combinations to see which one helps patients with advanced ovarian cancer live longer without disease progression after surgery. This trial involves patients who have undergone complete initial surgery.

Advanced Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Atopic Eczema: Dupilumab Dosing Study

We are studying how different dosing schedules of dupilumab affect people with controlled atopic eczema. The goal is to see which schedule works best for managing symptoms and improving quality of life.

Atopic Eczema3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Metastatic Melanoma: Diclofenac with PD-1 Inhibitor

We are studying whether adding diclofenac to ongoing PD-1 inhibitor therapy helps patients with metastatic melanoma who have stable disease. This trial aims to evaluate the potential benefits of this combination treatment.

Metastatic Melanoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesDermatologyOncology

Lumbar Spinal Surgery: Erector Spinae Plane Block

We are studying whether a specific pain management technique can reduce the need for morphine after lumbar spinal surgery. We will also look at recovery quality and any complications related to the procedure.

Patients Undergoing Lumbar ArthrodesisMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOrthopedics and TraumatologyOtolaryngology

Heart Procedure: Protamine Administration Study

We are comparing routine versus selective use of protamine during transcatheter aortic valve implantation to see which method better reduces bleeding and death risks after the procedure.

Aortic Stenosis≤3 monthsConfirmation phase (III)Monitoring phase (IV)Standard MedicinesCardiologyInternal Medicine

Community-Acquired Pneumonia: Customized Antibiotic Duration Study

We are investigating whether a new strategy for shortening antibiotic treatment is as effective as standard care for hospitalized patients with pneumonia. This study aims to improve patient outcomes while reducing unnecessary antibiotic use.

Community-acquired Pneumonia>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicinePulmonology

Glofitamab for Pediatric B-Cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of glofitamab alone and with other treatments for children and young adults with relapsed or refractory B-cell non-Hodgkin lymphoma. This research aims to find better options for managing this challenging cancer.

B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Elranatamab Treatment Study

We are studying the effectiveness of Elranatamab for patients with relapsed or refractory multiple myeloma who have already been treated with three different drug classes. This trial aims to see if it can help achieve better disease control.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Montelukast for Mild-Moderate Parkinson’s Disease

We are studying whether Montelukast can slow disease progression in people with mild to moderate Parkinson’s disease. The trial also examines its effects on symptoms and potential side effects.

Parkinson's Disease1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Pleural Mesothelioma: New Chemotherapy and Immunotherapy Study

We are exploring a new treatment combining chemotherapy and immunotherapy for patients with inoperable pleural mesothelioma. The study will evaluate treatment completion rates, side effects, and overall quality of life.

Inoperable Pleural Mesothelioma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Lower Respiratory Infections: Acyclovir Therapy

We are studying whether acyclovir can help ventilated patients with lower respiratory infections and herpes simplex virus. The trial aims to see if it improves survival and reduces hospital stays.

Pneumonia with Herpes Simplex Virus Infection6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

Dupilumab for Young Children with Uncontrolled Asthma

We are studying whether dupilumab can help reduce severe asthma attacks in children aged 2 to under 6 years. The trial will also evaluate the safety and tolerability of this treatment.

Asthma and Wheezing1-2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteAllergologyPediatricsPulmonology